/ /

  • linkedin
  • Increase Font
  • Sharebar

    New-generation presbyopia-correcting IOL

    Extended range of vision implant lives up to its name in U.S. IDE clinical trial

    Sioux City, IA—Results from the 6-month follow-up visit in a U.S. Investigational Device Exemption (IDE) clinical trial show that an investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott) provides better near and intermediate vision with reduced spectacle dependence after cataract surgery compared with a monofocal IOL, and it achieves those outcomes while maintaining good distance vision, said Jason Jones, MD.

    “The extended range of vision IOL has a novel optic design that aims to deliver a full range of high-quality uncorrected vision, and it seems to have met that goal based on the outcomes from the U.S. IDE clinical trial. According to the data in this study, patients who are bilaterally implanted with the extended range of vision IOL may expect an uncorrected visual acuity of about 20/20 at distance and intermediate and between 20/25 and 20/32 for near,” commented Dr. Jones, US IDE clinical trial investigator and president, Jones Eye Clinic, Sioux City, IA.

    Related: Treating presbyopia with an eye drop?

    “Patients receiving the extended range of vision IOL also did well in terms of safety and satisfaction with visual quality, and my patients who found any need for spectacles typically only used them perhaps once a week if they were reading very small print or in challenging light conditions.”

    The extended range of vision IOL merges two complementary technologies—a proprietary echellete design that elongates focus to extend the range of vision with a proprietary achromatic technology that reduces chromatic aberration for enhanced contrast sensitivity.

    More: What a novel scleral implant may mean for presbyopia

    The U.S. IDE clinical trial randomized 298 patients enrolled at 15 centers to bilateral implantation of the extended range of vision IOL or an aspheric acrylic 1-piece monofocal IOL (model ZCB00; Tecnis, Abbott). All but four patients were evaluable at 6 months.

    Outcomes assessed included visual acuity (VA) and defocus curve testing that was done monocularly after implantation of the first eye and after binocular implantation at the 6-month visit.

    Primary endpoint

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results